Search

Displaying results 8761 - 8770 of 9313 in total
  1. Drug

    CYNK-101

    go.drugbank.com/drugs/DB18637
    Investigational

    CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

    Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)
  2. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

  3. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.

  4. Drug

    Vaniprevir

    go.drugbank.com/drugs/DB11929
    Investigational

    Vaniprevir has been used in trials studying the treatment and diagnostic of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C Infection, and Chronic Genotype 1 Hepatitis C Virus

  5. Drug

    9CUAB30

    go.drugbank.com/drugs/DB12316
    Investigational

    9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among

  6. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

  7. Drug

    Hopantenic acid

    go.drugbank.com/drugs/DB14044
    Experimental

    Hopantenic acid has a unique spectrum of pharmacological effects (nootropic, anticonvulsant, mild activating) in the absence of addiction, hyperstimulation or withdrawal syndrome. [A33115]

  8. Drug

    CX-2009

    go.drugbank.com/drugs/DB16090
    Investigational

    CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

  9. Drug

    NTLA-2001

    go.drugbank.com/drugs/DB18525
    Investigational

    NTLA-2001 is a clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9.

  10. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    It is under investigation for the treatment of ovarian cancer.